Q1 2025 Earnings Call Transcript February 10, 2025 Arrowhead Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-1.39 EPS, expectations were $-0.42. Chris Anzalone: Thanks, Vince.

Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout ...

The National Kidney Foundation (NKF) has awarded Roger Rodby, MD, Professor of Medicine, Division of Nephrology at Rush University Medical Center, the Donald W. Seldin Award.  The distinguished honor ...

Intermittent fasting is becoming increasingly popular. But is it helpful for weight loss and other medical conditions?

Turmeric shots are a wellness drink that may offer many health benefits for their antioxidant and anti-inflammatory effects, ...

ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Plozasiran Update On January 17, 2025, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced that the U.S. Food and Drug Administration (FDA) ...

The blockbuster drug semaglutide, better known as Ozempic for diabetes and Wegovy for obesity, could also help people cut down on their alcohol intake, according to new USC research.

The National Institute for Nephrology Dialysis and Transplantation (NINDT) has planned a series of events to mark this ...

Groundbreaking research exposes how diabetes damages kidneys, offering hope through early detection and innovative prevention ...

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Jan. 27, 2025 — A study shows that patients with obesity and fatty liver-related cirrhosis who had bariatric (weight-loss) surgery significantly lowered their future ... Signposting Children to ...

The research, published recently in the journal Clinical Gastroenterology and Hepatology, found that people with belly fat or ...